Propanc Biopharma is a pre-revenue biopharmaceutical company developing proenzyme-based therapies designed to prevent cancer recurrence and metastasis in patients with solid tumors such as pancreatic, ovarian, and colorectal cancers. The company's lead product, PRP, is an intravenous formulation combining trypsinogen and chymotrypsinogen that targets cancer stem cells through a differentiation therapy approach intended to minimize toxicity to healthy tissue. Propanc pursues a capital-efficient, outsourced development model engaging contract research organizations and academic partners, with a strategy to seek licensing partnerships following clinical proof-of-concept, positioning itself in the broader metastatic cancer treatment market alongside chemotherapy, kinase inhibitors, monoclonal antibodies, and immunotherapies.